Reinventing radiation therapy with machine learning and imaging bio-markers (radiomics): State-of-the-art, challenges and perspectives.

Journal: Methods (San Diego, Calif.)
Published Date:

Abstract

Radiation therapy is a pivotal cancer treatment that has significantly progressed over the last decade due to numerous technological breakthroughs. Imaging is now playing a critical role on deployment of the clinical workflow, both for treatment planning and treatment delivery. Machine-learning analysis of predefined features extracted from medical images, i.e. radiomics, has emerged as a promising clinical tool for a wide range of clinical problems addressing drug development, clinical diagnosis, treatment selection and implementation as well as prognosis. Radiomics denotes a paradigm shift redefining medical images as a quantitative asset for data-driven precision medicine. The adoption of machine-learning in a clinical setting and in particular of radiomics features requires the selection of robust, representative and clinically interpretable biomarkers that are properly evaluated on a representative clinical data set. To be clinically relevant, radiomics must not only improve patients' management with great accuracy but also be reproducible and generalizable. Hence, this review explores the existing literature and exposes its potential technical caveats, such as the lack of quality control, standardization, sufficient sample size, type of data collection, and external validation. Based upon the analysis of 165 original research studies based on PET, CT-scan, and MRI, this review provides an overview of new concepts, and hypotheses generating findings that should be validated. In particular, it describes evolving research trends to enhance several clinical tasks such as prognostication, treatment planning, response assessment, prediction of recurrence/relapse, and prediction of toxicity. Perspectives regarding the implementation of an AI-based radiotherapy workflow are presented.

Authors

  • Laurent Dercle
    Department of Radiology, Columbia University Medical Center, 630 West 168th Street, New York, NY 10032; Gustave Roussy, Université Paris-Saclay, Université Paris-Saclay, Département D'imagerie Médicale, Villejuif, France.
  • Theophraste Henry
    Molecular Radiotherapy and Innovative Therapeutics, INSERM UMR1030, Gustave Roussy Cancer Campus, Université Paris Saclay, Villejuif, France; Department of Nuclear Medicine and Endocrine Oncology, Gustave Roussy Cancer Campus, Villejuif, France.
  • Alexandre Carré
    U1030 Molecular Radiotherapy, Paris-Sud University - Gustave Roussy - Inserm - Paris-Saclay University, Villejuif, France; Department of Medical Physics, Gustave Roussy - Paris-Saclay University, Villejuif, France.
  • Nikos Paragios
    TheraPanacea, Paris, France.
  • Eric Deutsch
    Gustave Roussy Cancer Campus, Villejuif, France.
  • Charlotte Robert
    U1030 Molecular Radiotherapy, Paris-Sud University - Gustave Roussy - Inserm - Paris-Saclay University, Villejuif, France; Department of Medical Physics, Gustave Roussy - Paris-Saclay University, Villejuif, France. Electronic address: ch.robert@gustaveroussy.fr.